share_log

BioNTech | 6-K: BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023

BioNTech | 6-K: BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023

BioNTech | 6-K:BioNTech在2023年ESMO大会上公布晚期实体瘤中CAR-T细胞疗法候选药物BNT211的1/2期阳性数据更新
SEC announcement ·  2023/10/23 16:16
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息